随着对控制心力衰竭(HF)发生的基础分子机制的了解逐渐加深,针对具体的病理进行治疗的可能性增大。目前的技术水平已能在体内有效地转入一个长期表达转基因的心肌组织。这样就能够将基础知识转化为临床的基因治疗。HF的基因治疗还在临床的“婴儿时期”,大量的经验都只来自动物 With a deeper understanding of the underlying molecular mechanisms that control heart failure (HF), there is an increased likelihood of treatment for specific pathologies. The current state of the art has been able to efficiently translocate into a long-term transgenic myocardial tissue in the body. This translates the basics into clinical gene therapy. Gene therapy for HF is still in clinical “infancy” and much of the experience comes from animals only